Suppressing microtubule detyrosination enhances AAV2-mediated factor IX gene transduction efficiency in liver cells and hemophilia B mouse models, offering a promising strategy for augmenting AAV-mediated gene therapy. This evidence concerns the gene F9 and hemophilia B.